Exelixis Inc Available-for-sale Securities, Amortized Cost Basis
Exelixis Inc (EXEL) had Available-for-sale Securities, Amortized Cost Basis of $440.76 million as of 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-26
- 2017-12-29: Available-for-sale Securities, Amortized Cost Basis $440.76M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $413.39M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $368.34M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $457.17M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-12-29 | $440.76M 10-K · filed 2018-02-26 | |
| 2017-09-30 | $413.39M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $368.34M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $457.17M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $460.27M 10-Q · filed 2017-11-01 | |
| 2016-12-30 | $460.27M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $366.03M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $374.56M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $405.19M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $250.81M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $279.80M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $164.96M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $193.89M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $238.30M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $289.61M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $348.30M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $406.75M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $409.72M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $464.54M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $524.53M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $566.69M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $628.36M 10-K · filed 2014-02-20 | $634.05M 10-K · filed 2013-02-21 |
| 2012-09-30 | $674.73M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $294.78M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $332.06M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $283.86M 10-K · filed 2013-02-21 | |
| 2010-12-31 | $256.92M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |